Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Could not find a price target of $17, but did find $7.50.
"The 1 analysts offering 12-month price forecasts for Nano Dimension Ltd have a median target of 7.50, with a high estimate of 7.50 and a low estimate of 7.50. The median estimate represents a +141.16% increase from the last price of 3.11."
https://money.cnn.com/quote/forecast/forecast.html?symb=NNDM
Brothcheld, Great post.
To answer your questions:
Q-What do you guys think?
A. --I really enjoyed reading the post, you really did some home work there. I really enjoyed the disclaimer.
Q- What do you guys think of the forecast?
A. --I have a low end estimate of $1,164,000 and a high end estimate of $1,397,000 so I think you are probably very close.
Q-What do you guys think of market reaction to either of these numbers?
A.-- In my opinion EVIO never reacts as well as I would expect to financials. We may see a 10%-20% boost but someone would immediately start selling into the run and send us in the other direction. LOL
I think if WW reduced the AS count we would see a nice run.
ALL IMHO
Not Sure if this has been posted yet. News out about the partnership in Florida, see article below.
"All of this comes as a result Martinez's partnership with Evio Labs, which he describes as being like the McDonald's of cannabis testing. It has a practically unrivaled foothold in this growing industry. In the past month, shares of Evio Inc. have jumped 201 percent, and a second lab in Florida is scheduled to open soon in Gainesville. So it's safe to say the business of marijuana is taking root in the Sunshine State."
http://www.miaminewtimes.com/news/whats-in-your-weed-touring-floridas-first-marijuana-testing-lab-9999158
Great 10K ....... If EVIO can get its reporting in order, I could see an up-list. EVIO is one of the best US MJ plays IMO. Just need to get some more attention, which will bring the volume with it. With two new MJ ETF's on the horizon that will have an investment strategy to include the US MJ sector, it is only a matter of time before the EVIO hits hits true potential.
I was trying to estimate the revenue the other night, what I have as an estimate is 3.2MM-3.4MM. I think we will definitely be at or slightly above 3 mil. However, mixed drinks and math do not complement one another, so I could be way off.
Looks like C3 is capable of more than just product testing.
Quality assurance from supply chain to retail
Raw Material Safety Screen
aflatoxins
mycotoxins
pesticides
Full Compound Profiling
potency
contaminants
heavy metals
residual solvents
moisture content
Purification and Processing
Supercritical fluid extraction (SFE)
Supercritical fluid chromatography (SFC)
Destearinization (Winterization)
Flavor blending
Concentration
Final Formulations
topical
vapor oil
sublingual
transdermal
edible
gelcap
Finish Product Testing
dissolution testing
stability testing
Quality Control
HPLC
GC/MS
LC/MS
Karl Fischer
Microbial Enumeration
QPCR
Same properties were moved in 2016 at the same valuation???
https://finance.yahoo.com/news/beverly-hills-group-inc-bhgi-131500072.html
QB Status back on OTC Market.
PR Shows in Fidelity
MMEX Resources Announces Strategic Relationship with Trinity Consultants on Crude Oil Refinery in Permian Basin
BY GlobeNewswire
— 12:55 PM ET 04/19/2017
AUSTIN, TEXAS, April 19, 2017 (GLOBE NEWSWIRE) -- MMEX Resources Corp. a development stage company focusing on the acquisition, development and financing of oil, gas, refining and infrastructure projects in Texas and South America, today announced a strategic relationship with Trinity Consultants, Inc., an international environmental consulting firm that specializes in industrial air quality issues.
Under the agreement, Trinity will assist MMEX with the necessary air quality environmental authorizations to initiate construction of the refinery including the New Source Review Prevention of Significant Deterioration (PSD) permit application required by the Texas Commission on Environmental Quality (TCEQ) and EPA Region 6, and subsequent Title V Federal Operating Permit. Trinity will also provide broad environmental support comprising preliminary environmental site feasibility evaluation, permitting strategy development, regulatory applicability analysis, and permit preparation, negotiation, and public participation.
Jack W. Hanks, President & CEO of MMEX Resources Corp. commented: “Plans for the Pecos County refinery are continuing to move forward quickly. Our agreement with Trinity, a world class group of environmental consultants who will be vital to securing the necessary permitting for the project, is the next logical step in this endeavor and we are thrilled to have them onboard our growing team.”
Brian Burdorf, Operations Director in Trinity’s Gulf/South region noted, “While the environmental permitting process for a new facility of this type is not inconsequential, our team is extremely experienced in understanding and meeting the requirements. We are pleased to be working with MMEX on this important new project and look forward to delivering exceptional results.”
In early March MMEX announced its intention to build a crude oil refinery in the Permian Basin near Fort Stockton, Texas, subject to the receipt of required governmental permits and completion of required debt and equity financing.
This announcement was followed by the formalizing of an agreement with KP Engineering, an energy industry leader in engineering, procurement and construction solutions which will engineer, design and construct the planned project, and an announcement that the two parties will subcontract with Interstate Treating, Inc./RAMA Fabrication, Inc. of Odessa, Texas to engineer and fabricate vessels and process modules for the refinery. The latter announcement allows for the Pecos County refinery to be constructed using U.S.-sourced materials and equipment.
The state-of-the-art refinery project, with plans to export crude oil, fuels and petroleum products to western Mexico and South America, would generate approximately 400 local jobs during peak construction and approximately 100 permanent jobs upon becoming fully operational.
Construction is slated to begin in early 2018, following the permitting process, and the facility is projected to begin operations in 2019.
About MMEX Resources is a development stage company formed to engage in the exploration, extraction, refining and distribution of oil, gas, petroleum products and electric power. MMEX focuses on the acquisition, development and financing of oil, gas, refining and electric power projects in Texas, Peru, and other countries in Latin America. For more information about MMEX, visit www.mmexresources.com.
About Trinity Consultants
Founded in 1974 in Dallas, Texas, Trinity operates in locations across the U.S. and in Canada, the U.K., China, and the Middle East. Trinity assists mostly industrial facilities with regulatory environmental compliance, specializing in air quality permitting and compliance management. In addition to environmental consulting, Trinity’s divisions provide environmental modeling software (BREEZE®), implement technology solutions for EHS information management (T3®), provide professional EHS training, support EHS staffing needs, and assist the life sciences industries with occupational health science and toxicology (SafeBridge Consultants®).
Media Inquiries
For MMEX Resources Danielle Urban
512-448-4950
durban@piercom.com
For Trinity Consultants:
Laura Redmon
972 661-8100
lredmon@trinityconsultants.com
MMEX Investor Inquiries
Please contact MMEX Resources Corp. directly at +1.855.880.0400 or
investorrelations@mmex.com
The following constitutes a "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, which could cause our actual results to differ materially from those described in the forward looking statements. These risks include but are not limited to the Company’s ability to continue as a going concern, our lack of revenues, general business conditions, the requirement to obtain significant financing to pursue our business plan, our history of operating losses and other risks detailed from time to time in the Company's SEC reports. In particular, readers should note MMEX undertakes no obligation to update forward-looking statements.
I agree the 10K was not earth shattering but what company involved in medical trials with no dugs out to market is making tons of money? Valuation is not only based on revenue, sometimes you are investing in the a companies future.
The Multiple Myeloma results if accurate are truly remarkable and would be worth a very large sum to any company that was interested in licensing the drug, or a buy out.
But I am just an oil guy, what do I know.
misterf, I have really enjoyed reading your posts. I don't know how you have the time to keep up with all of the questions coming your way. I will say you have been spot on with all of your reply's and I agree with you 100%.
I myself have been in the Texas oil industry for 16 years and when I heard there was going to be a refinery built I was exited and a little skeptical with it being about 40 years since the last refinery was built. However, after some thought, doing some research, and speaking with coworkers and other individuals in the industry, this refinery makes perfect since. There has not been a more opportune time to build a refinery, Mexico’s growing economy (refined product demand), Trump in the White House, the roll back of local and federal regulations.
The access to easily refined Texas Crude and its intended purpose of sending products to Mexico, the planned location for the refinery almost couldn't be any better.
I know there is always a risk with investing but I hold shares in MMEX and look forward to the next two years. MMEX LONG….GLTA
Get off the ask, Let this thing run, and let those who waited chase.
VERY much related to EVERTHING going on here. Read the article. I am not saying dump your stock and run, just making everyone aware of news out there. I thought that was what these forums were for?
NEJM paper links 3 blinded patients to publicly-traded stem cell clinic
Posted on March 15, 2017
Do 3 blinded stem cell clinic patients with major or complete vision loss constitute a significant adverse outcome?
I would say so and a new paper details how this happened apparently at a particular publically-traded South Florida stem cell clinic business.
You can see the damaged retinas of one such patient below in an image from a new NEJM paper reporting the severe adverse outcomes. The red areas are hemorrhaging with other substantial damage to the retina as well.
How did this all happen?
Last year the story began to break of multiple patients alleging they had been blinded by different businesses in South Florida. Dr. Thomas Albini presented on some information on this at the FDA meeting last fall, but things weren’t entirely clear. Back then there were also indications of lawsuits by patients related to alleged vision loss due to experimental stem cell offerings against various parties involved.
Now we have more details on some of the cases in this new NEJM article (Kuriyan, et al.) in which the authors attribute these patients’ experiences to a withdrawn “trial”, NCT02024269, which lists Bioheart (now known as US Stem Cell, Inc.) as the sponsor. I put “trial” in quotes because it was withdrawn and also because as best as I can tell this wasn’t a traditional FDA-approved trial of the kind normally based on pre-clinical data and an IND. US Stem Cell, Inc. is a publicly-traded company ($USRM) and its stock has been all over the place this year. I’m not aware of US Stem Cell having FDA approval for what it is doing.
The NEJM article oddly does not mention Bioheart or US Stem Cell, Inc. by name as the place where the patients were given the stem cells, but the authors do clearly link them together and other information further supports this connection.
For example, US Stem Cell, Inc. leader Kristin Comella acknowledged last year in an NPR interview that two of their patients had retinal detachment following interventions received from the company. From NPR:
“Comella acknowledges that two of her clinic’s patients suffered detached retinas after getting stem cells injected into their eyes. As a result, the clinic has stopped treating eye conditions.”
You can read my 2015 interview with Comella here. I have reached out to her more recently to ask for her perspectives on the situation with these patients, but gotten no reply.
The NEJM article goes through the cases of the three blinded stem cell clinic patients who had received adipose stem cell injections into their eyes:
“We report three cases of vision loss after patients with AMD received bilateral intravitreal injections of autologous adipose tissue-derived stem cells at a stem-cell clinic, which was the study site for the fourth trial described above (NCT02024269). After treatment, in June 2015, the patients were referred to two university-based ophthalmology practices.”
There are so many questions here.
Why would someone think that fat stem cells could be used safely and effectively in eyes? To me as a stem cell biologist that doesn’t make sense.
Why would an IRB approve this kind of risky approach?
Why did they inject into both eyes at once?
And a biggie: if preclinical testing had been done and rodents had been given equivalent transplants, would some of the animals have gone blind? If so, could that have prevented this tragedy?
Since US Stem Cell, through a subsidiary called US Stem Cell Training, sells some kind of stem cell training to others to do stem cell interventions, is that spreading risks to patients even further? Notably on the US Stem Cell Training website none of the personnel listed as doing the stem cell clinical training are MDs. Why is that?
Is this just the tip of the iceberg for negative stem cell clinic outcomes given that there are around 600 such clinics in the US today largely operating generally without FDA approvals, lacking preclinical data to support what they are doing, and experimenting on thousands of patients for profit?
NOT GOOD… Stem-Cell Clinic’s Treatments Left Three Patients Blind
insert-text-here
insert-text-here
Anyone know if the contestants on the LFC home page are potential fighters or if they're auditioning to be fighters? I was looking at the home page and noticed the contestant section, after googling the first contestant name it appears that Porn-star Agatha Delicious is one of the contestant section of the LFC home page. Not sure what kind of following she has but Agatha may be an interesting addition.
IMO With the new AG (Sessions) just being signed into office, I would say SGBY is looking like an even better investment choice (for the MJ sector anyway). Even if recreational MJ is done away with, there will still be a need to test medical grade MJ and the number of patient subscribers just continues to grow.
Putting this out there please feel free to correct me if I am wrong.
Oregon produces 1.3 million pounds of wet cannabis per year, once dried the testable weight of that marijuana is estimated to be 400,000 pounds (or 40,000 batches/lots to be tested). Oregon has 19 accredited labs in the state, assuming an equal share of the cannabis is tested at each lab (2,105 batches/lots), and considering that SGBY has 4 Labs in Oregon. The estimated number of batches tested by SGBY labs would be around 8,420. Now if we use $315.00 as the average cost per compliance test (http://www.greenleaflab.org/pricing/) the yearly average sales from testing alone would be approx. $2,652,300 or $663,075 per quarter. Now if you include the oils testing, failed tests, miscellaneous testing for average consumers, and consulting, this number could be even higher.
Now consider there are 377 licensed MJ producers in Oregon as of 1/18/17 currently producing the estimated 400K lbs and there are 676 (Producer) applications pending.
19 of which are approved and just awaiting payment, 415 assigned to investigator and under review, 119 applications ready to be assigned for review, and another 123 applications needing to submit (LUCS) Land Use Compatibility Statement
Add in the california lab and in IMO this company and those like it have a huge growth opportunity ahead.
All information contained in this post reflects my own opinion or the opinion of others and is intended for informational purposes only. Errors may exist.
I am not a professional broker nor can I offer buying advice, selling advice or recommendations concerning this post. Each person is responsible for their own buying and selling decisions of any stock openly traded. Any trade risks the possibility of losing the funds invested. Please do your own due diligence before making any investment decisions.
I am long on SGBY
https://www.oregon.gov/olcc/marijuana/Documents/mj_app_stats_
OREGON LIQUOR CONTROL COMMISSION
Marijuana License Applications
As of 8:00 AM January 18, 2017
OLCC Status Definitions
377-Approved applicant has paid license fee. OLCC has issued the license. Identified as “Active” in the licensing system.
19-OLCC has approved the application. Applicant has not paid the license fee. Identified as “Pending License Payment” in the licensing system.
415-Application is assigned to an investigator and is under OLCC review. Identified as “Assigned” in the licensing system.
119-Applicant has submitted a completed Land Use Compatibility Statement (LUCS) signed by the applicant’s local government, and is awaiting assignment to an investigator. Identified as “Local Government Review” in the licensing system.
123-Applicant has submitted an application but has not submitted a completed Land Use Compatibility Statement (LUCS) signed by the applicant’s local government. Identified as “New” in the licensing system.
Yeah..they do a pretty bad job at promoting
Should Call the local Breastaurants (Hooters, Twin Peaks, etc..) to ensure the fight will be showing.
Source: Cannabis Science Misrepresents in Press Releases
January 6, 2017 at 2:09 pm
Exclusive article by Alan Brochstein, CFA
Based in Houston, Alan leverages his experience as founder of online communities 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV.
Cannabis Science Misrepresents in Press Releases
Cannabis stocks are hot, with trading volumes remaining strong into 2017 after a 88% rise in the Cannabis Stock Index last year, with all of the gains coming after August. Many companies are taking advantage of the enthusiasm among traders, including stock promoters, newsletter writers and the publicly-traded companies as well.
This morning, Cannabis Science (OTC: CBIS) published a press release with a promising headline:
Cannabis Science Inc. (CBIS) and Dana Farber/Harvard Cancer Center (DF/HCC) Announce Joint Research and Drug Development Agreement; Collaborative Research Agreement
CBIS is one of the first publicly-traded cannabis-related stocks, with a debut in 2009. In its almost seven years of operations, it has demonstrated little success except in greatly expanding the number of shares outstanding (now over 2.3 billion as of November 7th). Insiders have been heavy sellers of the stock, often after press releases.
As part of my due diligence, I contacted Dana Farber/Harvard Cancer Center to verify that they are indeed a partner with CBIS. The press release stated: “Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medications, is proud to announce a collaborative research agreement with Dana Farber/Harvard Cancer Center (DF/HCC).”
Here is the response I received:
Hi Mr. Brochstein,
First, to aid in the discussion that may follow, I wanted to draw attention to the difference between Dana-Farber Cancer Institute (DFCI), and Dana-Farber/Harvard Cancer Center (DF/HCC). The latter is a consortium made up of 7 different institutions in Boston, one of which being DFCI. With that said, DF/HCC has no such agreement with Cannabis Science Inc., and we have begun the process to request a retraction/correction to this story. Since I only represent DF/HCC, not DFCI, I cannot know if such an agreement exists between DFCI and Cannabis Science, Inc. I hope this answers your question.
Kind Regards,
Richard P. Oakley
Communications | Dana-Farber/Harvard Cancer Center
10 Brookline Place, BP339B | Boston, MA 02215
Traders and investors should always be cautious with OTC company press releases. I fact-checked a prior press release from CBIS regarding its arrangement with a dispensary in California and was told that CBIS was not authorized to disclose it as a customer and that CBIS had exaggerated the relationship. CBIS files with the SEC, but it has not filed an 8-K yet regarding this alliance. It’s possible that CBIS incorrectly described its partner. Harvard certainly is the type of institution that can excite penny stock traders. CEO Ray Dabney heavily promoted his recent speech there, issuing three separate press releases about the event:
•09/26/16: Mr. Raymond C. Dabney, CBIS CEO, Accepts Invitation to Speak at Harvard Medical School
•10/27/16: As Cannabis Science CEO Prepares to Speak at Harvard Medical School This November 2016, Company Announces Clinical Research Studies to Begin Next Month As Well
•11/08/16: CBIS CEO, Mr. Dabney Prepares for Exclusive Harvard Medical School Drug Development Briefing as the Nation Votes on a Number of Historic Events
•11/21/16: Harvard Director of Global Health Catalyst at the World-Renowned Dana Farber/Harvard Cancer Center States: Cannabis Science Presentation and Discussions a Great Success for Mutually Beneficial Partnership Opportunities with Harvard Medical School
We asked about this last press release as well in a follow up with Mr. Oakley:
This was also a misprint which I asked to be corrected without success back in November. Dana-Farber/Harvard Cancer Center, being a collection of institutions, has no real location of its own, and from what I gathered by reading the article, it seems like Mr. Dabney must have presented at Harvard Medical School (HMS). While HMS is a DF/HCC member institution, DF/HCC did not arrange this event, and we assume DF/HCC was mentioned in the article out of confusion by the writer.
It’s not clear why a prestigious institution would team up with CBIS. According to the 10-Q for the quarter ending 9/30, the company had just $11,000 in cash. Its liabilities of $5.4mm greatly exceed its assets of $1.1mm, and its quarterly sales were just $2733. The company spent over $267K in the first three quarters on investor relations, exceeding the amount it spent on research and development costs. The company has been in business for almost 7 years but doesn’t seem to have demonstrated any success to date. It’s great that an institution like DF/HCC or even DFCI, if that is the correct party, would pursue cannabis research, but it is not clear why they would partner with this company.